Your browser doesn't support javascript.
loading
Antibody-mediated SARS-CoV-2 entry in cultured cells.
Kibria, Md Golam; Lavine, Christy L; Tang, Weichun; Wang, Shaowei; Gao, Hailong; Shi, Wei; Zhu, Haisun; Voyer, Jewel; Rits-Volloch, Sophia; Bi, Caihong; Peng, Hanqin; Wesemann, Duane R; Lu, Jianming; Xie, Hang; Seaman, Michael S; Chen, Bing.
Affiliation
  • Kibria MG; Division of Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
  • Lavine CL; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Tang W; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Wang S; Laboratory of Pediatric and Respiratory Viral Diseases, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
  • Gao H; Codex BioSolutions, Inc., Rockville, MD, USA.
  • Shi W; Division of Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
  • Zhu H; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Voyer J; Division of Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
  • Rits-Volloch S; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Keerti; Institute for Protein Innovation, Harvard Institutes of Medicine, Boston, MA, USA.
  • Bi C; Division of Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
  • Peng H; Division of Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
  • Wesemann DR; Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA.
  • Lu J; Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA.
  • Xie H; Division of Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
  • Seaman MS; Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Ragon Institute of MGH, MIT and Harvard, Boston, MA, USA.
  • Chen B; Codex BioSolutions, Inc., Rockville, MD, USA.
EMBO Rep ; 24(12): e57724, 2023 Dec 06.
Article in En | MEDLINE | ID: mdl-38277394
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by first engaging its cellular receptor angiotensin converting enzyme 2 (ACE2) to induce conformational changes in the virus-encoded spike protein and fusion between the viral and target cell membranes. Here, we report that certain monoclonal neutralizing antibodies against distinct epitopic regions of the receptor-binding domain of the spike can replace ACE2 to serve as a receptor and efficiently support membrane fusion and viral infectivity in vitro. These receptor-like antibodies can function in the form of a complex of their soluble immunoglobulin G with Fc-gamma receptor I, a chimera of their antigen-binding fragment with the transmembrane domain of ACE2 or a membrane-bound B cell receptor, indicating that ACE2 and its specific interaction with the spike protein are dispensable for SARS-CoV-2 entry. These results suggest that antibody responses against SARS-CoV-2 may help expand the viral tropism to otherwise nonpermissive cell types with potential implications for viral transmission and pathogenesis.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: En Journal: EMBO Rep Journal subject: BIOLOGIA MOLECULAR Year: 2023 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: En Journal: EMBO Rep Journal subject: BIOLOGIA MOLECULAR Year: 2023 Type: Article Affiliation country: United States